CDER asks FDA to re­voke Mak­e­na's ac­cel­er­at­ed ap­proval less than a week af­ter AM­AG ac­qui­si­tion

5 years ago
FDA+

GSK, As­traZeneca plan to har­ness AI pow­er for drug de­vel­op­ment from Nvidi­a's new, $50M-plus su­per­com­put­er now un­der ...

5 years ago
R&D
AI

Neil Ku­mar bets near­ly $1B on what Bridge­Bio hopes will be their first big drug

5 years ago
Deals
R&D

News brief­ing: Kro­nos Bio sets terms for IPO, flirt­ing with bil­lion-dol­lar uni­corn val­u­a­tion; Corvus col­labs with ...

5 years ago
News Briefing

Af­ter weath­er­ing fail­ure, re­jec­tion and lay­offs, Im­muno­Gen touts a new 'break­through' drug in its come­back plan

5 years ago
R&D
FDA+

Har­vard 'MacArthur ge­nius’ Kevin Eggan steps in to run ear­ly-stage re­search at rare dis­ease spe­cial­ist Bio­Marin

5 years ago
People
R&D

Covid-19 roundup: Top an­a­lyst: Re­gen­eron EUA like­ly this week — un­less Trump takes a turn for worse; UK says less ...

5 years ago
Coronavirus

Three sci­en­tists win No­bel Prize in Med­i­cine for work in dis­cov­er­ing he­pati­tis C virus

5 years ago
People
Discovery

With Covid-19 muck­ing the tires, Robert Dug­gan throws an­oth­er $50M be­hind his big an­tibi­otics play

5 years ago
R&D

Op­di­vo/Yer­voy com­bo flops again in melanoma, but Bris­tol My­ers Squibb al­so has a new OK to cel­e­brate

5 years ago
R&D
Pharma

Bris­tol My­ers of­fers a big pre­mi­um to reel in MyoKar­dia's car­dio pipeline with a $13B buy­out

5 years ago
Deals

Ran­somware at­tack hit clin­i­cal tri­als soft­ware play­er ERT — two weeks lat­er, they’re com­ing back on­line

5 years ago
Outsourcing
Pharma

Our 3rd an­nu­al UK bio­phar­ma event tops this week — on Zoom — with José Basel­ga, top biotech CEOs and a look at ...

5 years ago
Editor's note

What hap­pens when the N-of-1 is the pres­i­dent of the US? Re­gen­eron is about to find out

5 years ago
R&D
Coronavirus

Two top ex­ecs in Sanofi's R&D group are hit­ting the ex­it in a shake­up as Frank Nes­tle moves up to CSO

5 years ago
People

Dems slam drug pric­ing strate­gies as 18-month probe comes to an end

5 years ago
Pharma

Phar­ma vet Va­le­ria Fan­tin jumps to on­col­o­gy team at Gilead; João Sif­fert out as Abeona looks for an­oth­er CEO

5 years ago
Peer Review

The FDA hands Farx­i­ga 'break­through' sta­tus in CKD, clear­ing path for As­traZeneca's much-tout­ed ther­a­py

5 years ago
R&D
FDA+

Mer­ck R&D chief Roger Perl­mut­ter is hand­ing off the big job to the ex­ec in charge of dis­cov­ery

5 years ago
People
R&D

C4's An­drew Hirsch blows up IPO to $182M, while on­colyt­ic virus up­start nabs $87M of­fer­ing

5 years ago
People
Financing

FDA gives thumbs down for Mesoblast's aGVHD drug, say­ing one sin­gle-arm tri­al is not enough

5 years ago
Cell/Gene Tx
FDA+

Cor­moran­t's Bi­hua Chen joins the SPAC game, look­ing to raise $100M for a com­pa­ny that match­es 5 key cri­te­ria

5 years ago
Financing

Covid-19 roundup: As­traZeneca re­sumes vac­cine tri­als in Japan; Glob­al lab net­work is es­tab­lished to com­pare Covid-19 ...

5 years ago
Coronavirus

Alone in the spot­light, Pfiz­er CEO Bourla swears pure in­ten­tions in the rush to de­vel­op a Covid-19 vac­cine. But will ...

5 years ago
Bioregnum
Opinion
First page Previous page 794795796797798799800 Next page Last page
A service from the Financial Times